These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 21214510)

  • 41. Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.
    Jiang WG; Ye L; Ji K; Frewer N; Ji J; Mason MD
    Int J Oncol; 2012 Nov; 41(5):1635-42. PubMed ID: 22971748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Development of FAK Inhibitors: A Five-Year Update.
    Spallarossa A; Tasso B; Russo E; Villa C; Brullo C
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
    Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
    Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progress in researches about focal adhesion kinase in gastrointestinal tract.
    Hao HF; Naomoto Y; Bao XH; Watanabe N; Sakurama K; Noma K; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Takaoka M
    World J Gastroenterol; 2009 Dec; 15(47):5916-23. PubMed ID: 20014455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
    Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
    BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of focal adhesion kinase in human cancer: a potential target for drug discovery.
    Han EK; McGonigal T
    Anticancer Agents Med Chem; 2007 Nov; 7(6):681-4. PubMed ID: 18045062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FAK expression regulation and therapeutic potential.
    Li S; Hua ZC
    Adv Cancer Res; 2008; 101():45-61. PubMed ID: 19055942
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence.
    Quispe PA; Lavecchia MJ; León IE
    Drug Discov Today; 2022 Feb; 27(2):664-674. PubMed ID: 34856395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Src and focal adhesion kinase as therapeutic targets in cancer.
    Brunton VG; Frame MC
    Curr Opin Pharmacol; 2008 Aug; 8(4):427-32. PubMed ID: 18625340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
    Ward KK; Tancioni I; Lawson C; Miller NL; Jean C; Chen XL; Uryu S; Kim J; Tarin D; Stupack DG; Plaxe SC; Schlaepfer DD
    Clin Exp Metastasis; 2013 Jun; 30(5):579-94. PubMed ID: 23275034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study.
    Gao J; Cheng J; Xie W; Zhang P; Liu X; Wang Z; Zhang B
    Expert Opin Investig Drugs; 2024 Jun; 33(6):639-651. PubMed ID: 38676368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FERM control of FAK function: implications for cancer therapy.
    Lim ST; Mikolon D; Stupack DG; Schlaepfer DD
    Cell Cycle; 2008 Aug; 7(15):2306-14. PubMed ID: 18677107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computational-based discovery of FAK FERM domain chemical probes that inhibit HER2-FAK cancer signaling.
    Stahl E; Nott R; Koessel K; Cance W; Marlowe T
    Chem Biol Drug Des; 2020 Jun; 95(6):584-599. PubMed ID: 32080977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials.
    Mohanty A; Pharaon RR; Nam A; Salgia S; Kulkarni P; Massarelli E
    Expert Opin Investig Drugs; 2020 Apr; 29(4):399-409. PubMed ID: 32178538
    [No Abstract]   [Full Text] [Related]  

  • 55. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic conformational changes in the FERM domain of FAK are involved in focal-adhesion behavior during cell spreading and motility.
    Papusheva E; Mello de Queiroz F; Dalous J; Han Y; Esposito A; Jares-Erijmanxa EA; Jovin TM; Bunt G
    J Cell Sci; 2009 Mar; 122(Pt 5):656-66. PubMed ID: 19208768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crystal structure of the FERM domain of focal adhesion kinase.
    Ceccarelli DF; Song HK; Poy F; Schaller MD; Eck MJ
    J Biol Chem; 2006 Jan; 281(1):252-9. PubMed ID: 16221668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
    Serrels A; McLeod K; Canel M; Kinnaird A; Graham K; Frame MC; Brunton VG
    Int J Cancer; 2012 Jul; 131(2):287-97. PubMed ID: 21823119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Focal adhesion kinase regulates collagen I-induced airway smooth muscle phenotype switching.
    Dekkers BG; Spanjer AI; van der Schuyt RD; Kuik WJ; Zaagsma J; Meurs H
    J Pharmacol Exp Ther; 2013 Jul; 346(1):86-95. PubMed ID: 23591997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
    Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
    Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.